<DOC>
<DOCNO>EP-0627413</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31165	A61K31165	A61P900	A61P900	A61P906	A61P908	A61P910	C07C27700	C07C27708	C07C27900	C07C27922	C07C31100	C07C31115	C07C31700	C07C31744	C07C31746	C07C32300	C07C32362	C07D24100	C07D24128	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	A61P	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	A61P9	A61P9	A61P9	C07C277	C07C277	C07C279	C07C279	C07C311	C07C311	C07C317	C07C317	C07C317	C07C323	C07C323	C07D241	C07D241	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
There are described benzoylguanidines of the formula I 
<
IMAGE
>
  where   R(1) is H, Hal, -NO2, -C IDENTICAL N, Xo-(CH2)p-(CF2)q-CF3, R(5)- SOm, R(6)-CO- or R(6)R(7)NO-SO2-, where X is O, S, NR(14), m is 0-2, o is 0, 1, p is 0-2, q is 0-6, R(5) and R(6) are alk(en)yl, -CnH2n-R(8), CF3, n is 0-4, R(8) is cycloalkyl, phenyl, R(6) also being H,   R(2) is 
<
IMAGE
>
 where Y is O, -S- or -NR(12)-; R(11), R(12) = H, alkyl, and h is zero or 1, and i, j and k are 0-4,  but where h, i and k are not simultaneously zero, R(3) is defined as R(1), or is alkyl, -X-R(13) where X is O, S, NR(14), R(14) is H, alkyl, R(13) is H, (cyclo)alkyl, -CbH2b-R(15) where b is 0-4,  R(15) is phenyl,   R(4) is H, -OR(16) or -NR(16)R(17) where R(16), R(17) are H, alkyl  and their pharmaceutically tolerable salts. They are obtained from a compound II 
<
IMAGE
>
 by reaction with guanidine, in which R(1) to R(4) have the meaning indicated and L is a leaving group which can be easily nucleophilically substituted. The compounds are outstandingly suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and also for the treatment of angina pectoris, where they also preventively inhibit or severely decrease the pathophysiological processes in the formation of ischaemically induced damage, in particular in the elicitation of ischaemically induced cardiac arrhythmias.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOECHST AG
</APPLICANT-NAME>
<APPLICANT-NAME>
HOECHST AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ALBUS UDO DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEEMANN HEINZ-WERNER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
LANG HANS-JOCHEN DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOLZ WOLFGANG DR
</INVENTOR-NAME>
<INVENTOR-NAME>
ALBUS, UDO, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEEMANN,HEINZ-WERNER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
LANG, HANS-JOCHEN, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHOLZ, WOLFGANG, DR.
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
